Who are Isobide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monoket, Nitroglycerin, NITROGLYCERIN, Monoket Pill, Glyceryl trinitrate 0.2, Nitroglycerin infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isosorbide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Isobide — Competitive Intelligence Brief

Isobide (ISOSORBIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrate Vasodilator [EPC]. Area: Cardiovascular.

marketed Nitrate Vasodilator [EPC] Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Isobide (ISOSORBIDE) — Novartis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Isobide TARGET	ISOSORBIDE	Novartis	marketed	Nitrate Vasodilator [EPC]		1974-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
Nitroglycerin	glyceryl trinitrate	Fougera	marketed	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
NITROGLYCERIN	NITROGLYCERIN		marketed	Nitrate Vasodilator [EPC]	Nitric oxide synthase pathway	1981-01-01
Monoket Pill	Monoket Pill	Ohio State University	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Glyceryl trinitrate 0.2	Glyceryl trinitrate 0.2	Recep Tayyip Erdogan University	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Nitroglycerin infusion	Nitroglycerin infusion	Tri-Service General Hospital	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Nitroglycerin · 7872049 · US
2029-03-12 — NITROGLYCERIN · 7872049 · Formulation · US
2032-03-11 — Nitroglycerin · 9101592 · US
2032-03-11 — NITROGLYCERIN · 9101592 · Formulation · US

Sponsor landscape (Nitrate Vasodilator [EPC] class)

· 2 drugs in this class
Centre for Addiction and Mental Health · 1 drug in this class
Fougera · 1 drug in this class
Novartis · 1 drug in this class
Stefan Fischli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isobide — Competitive Intelligence Brief. https://druglandscape.com/ci/isosorbide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab